Meloxicam Cinfa (Meloxicam)

Meloxicam works by preferentially inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which lowers the production of prostaglandins—chemical mediators that cause inflammation, pain, and fever. This selective inhibition provides anti‑inflammatory benefits while sparing COX‑1 activity to a greater extent.

The dosage of meloxicam is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Typical adult dosing ranges are established in clinical guidelines, but the exact regimen should be individualized by a healthcare professional.

Safety of meloxicam during pregnancy and lactation has not been established. Because of potential risks to the fetus or infant, it is generally avoided unless the benefits clearly outweigh the risks and no safer alternative is available.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Meloxicam offers a longer half‑life and a higher selectivity for COX‑2 compared with many traditional NSAIDs such as ibuprofen or naproxen. This may allow once‑daily dosing and potentially lower gastrointestinal risk, though individual response and safety profiles vary.

Store the product at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Meloxicam Cinfa is administered orally, usually as a whole tablet swallowed with water. It should be taken with or without food as directed by the prescriber, and the patient should follow any specific instructions regarding timing or concomitant medications.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), and renal impairment. Patients should seek immediate medical attention if they experience symptoms like severe abdominal pain, sudden weakness, rash, or reduced urine output.

Meloxicam should be avoided in patients with known hypersensitivity to meloxicam or other NSAIDs, active gastrointestinal ulcer disease, severe heart failure, uncontrolled hypertension, advanced renal or hepatic impairment, and in those who are pregnant or breastfeeding unless absolutely necessary.